Patent Issued for Glucose glycans for treating urea cycle disorders (USPTO 12090168).

A patent has been issued for the use of glucose glycans in treating urea cycle disorders (UCDs) and hepatic encephalopathy (HE). The glycan preparations described in the patent can be used to increase or decrease enzymatic activities, modulate the processing of metabolites, and identify treatment regimens for UCD patients. The patent also includes specific methods for administering the glycan preparations and their formulations. This invention provides a potential novel therapy for UCDs and HE, addressing the need for effective treatment options in maintaining or restoring human health. [Extracted from the article]